Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NASDAQ:DERM NASDAQ:FBIO NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.38+0.7%$2.09$1.11▼$5.00$364.61M1.874.05 million shs3.92 million shsDERMJourney Medical$7.23-3.0%$7.28$3.54▼$8.90$196.01M0.8167,357 shs161,558 shsFBIOFortress Biotech$3.86+7.5%$2.21$1.33▼$3.91$106.82M1.611.15 million shs1.45 million shsSTOKStoke Therapeutics$22.66+2.7%$15.56$5.35▼$22.79$1.21B1.141.07 million shs1.07 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-4.20%-2.84%-41.20%-38.84%-66.50%DERMJourney Medical+6.28%+4.63%-1.59%+7.81%+54.24%FBIOFortress Biotech-0.28%+20.47%+97.25%+70.95%+101.69%STOKStoke Therapeutics+0.36%+12.66%+68.47%+91.91%+43.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.38+0.7%$2.09$1.11▼$5.00$364.61M1.874.05 million shs3.92 million shsDERMJourney Medical$7.23-3.0%$7.28$3.54▼$8.90$196.01M0.8167,357 shs161,558 shsFBIOFortress Biotech$3.86+7.5%$2.21$1.33▼$3.91$106.82M1.611.15 million shs1.45 million shsSTOKStoke Therapeutics$22.66+2.7%$15.56$5.35▼$22.79$1.21B1.141.07 million shs1.07 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-4.20%-2.84%-41.20%-38.84%-66.50%DERMJourney Medical+6.28%+4.63%-1.59%+7.81%+54.24%FBIOFortress Biotech-0.28%+20.47%+97.25%+70.95%+101.69%STOKStoke Therapeutics+0.36%+12.66%+68.47%+91.91%+43.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.12560.87% UpsideDERMJourney Medical 2.50Moderate Buy$12.1768.28% UpsideFBIOFortress Biotech 3.00Buy$16.50327.46% UpsideSTOKStoke Therapeutics 3.22Buy$25.5712.85% UpsideCurrent Analyst Ratings BreakdownLatest DERM, FBIO, AUTL, and STOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025DERMJourney MedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.008/21/2025FBIOFortress BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $17.008/18/2025STOKStoke TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$28.008/15/2025DERMJourney MedicalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/13/2025AUTLAutolus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$6.00 ➝ $5.008/13/2025DERMJourney MedicalLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $13.008/13/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/13/2025STOKStoke TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$16.00 ➝ $22.007/21/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.007/18/2025STOKStoke TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.007/1/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$10.12M36.29N/AN/A$1.61 per share0.86DERMJourney Medical$56.13M3.39N/AN/A$0.91 per share7.95FBIOFortress Biotech$57.67M1.99N/AN/A($0.06) per share-64.33STOKStoke Therapeutics$36.56M33.97N/AN/A$4.32 per share5.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$220.66M-$0.84N/AN/AN/AN/A-56.18%-29.61%11/11/2025 (Estimated)DERMJourney Medical-$14.67M-$0.38N/AN/AN/A-15.49%-48.69%-11.26%11/11/2025 (Estimated)FBIOFortress Biotech-$46M-$1.05N/AN/AN/A-24.84%-301.81%-27.48%11/13/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.8526.66N/AN/A26.25%18.32%15.48%11/4/2025 (Estimated)Latest DERM, FBIO, AUTL, and STOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FBIOFortress Biotech-$0.31-$0.46-$0.15$0.45$14.53 million$16.41 million8/12/2025Q2 2025AUTLAutolus Therapeutics-$0.24-$0.18+$0.06-$0.18$12.92 million$13.50 million8/12/2025Q2 2025DERMJourney Medical-$0.07-$0.16-$0.09-$0.16$14.93 million$15.01 million8/12/2025Q2 2025STOKStoke Therapeutics-$0.57-$0.40+$0.17-$0.40$31.51 million$13.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A8.438.07DERMJourney Medical1.111.270.95FBIOFortress Biotech1.341.921.70STOKStoke TherapeuticsN/A6.986.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%DERMJourney Medical7.25%FBIOFortress Biotech96.51%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%DERMJourney Medical15.03%FBIOFortress Biotech27.90%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableDERMJourney Medical9026.31 million22.36 millionN/AFBIOFortress Biotech17029.75 million21.45 millionOptionableSTOKStoke Therapeutics10054.80 million49.59 millionOptionableDERM, FBIO, AUTL, and STOK HeadlinesRecent News About These CompaniesStoke Therapeutics (NASDAQ:STOK) Hits New 1-Year High - Still a Buy?September 10 at 12:16 PM | marketbeat.comStoke Therapeutics, Inc. $STOK Shares Sold by Trexquant Investment LPSeptember 10 at 3:13 AM | marketbeat.comInvesco Ltd. Raises Stock Holdings in Stoke Therapeutics, Inc. $STOKSeptember 10 at 3:03 AM | marketbeat.comStoke Therapeutics, Inc. $STOK Shares Bought by Granahan Investment Management LLCSeptember 7 at 6:20 AM | marketbeat.comStoke Therapeutics, Inc. $STOK is Checkpoint Capital L.P.'s 7th Largest PositionSeptember 6, 2025 | marketbeat.com16,119 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Russell Investments Group Ltd.September 6, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 850 Shares of StockSeptember 5, 2025 | marketbeat.comEdward Md Kaye Sells 1,029 Shares of Stoke Therapeutics (NASDAQ:STOK) StockSeptember 5, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 5,501 SharesSeptember 5, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 6,345 SharesSeptember 5, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells $299,280.40 in StockSeptember 5, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) General Counsel Sells $300,529.08 in StockSeptember 5, 2025 | marketbeat.comEdward Md Kaye Sells 45,996 Shares of Stoke Therapeutics (NASDAQ:STOK) StockSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Buys Shares of 30,085 Stoke Therapeutics, Inc. $STOKSeptember 5, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Hits New 1-Year High - Here's WhySeptember 4, 2025 | marketbeat.comRedmile Group LLC Sells 107,648 Shares of Stoke Therapeutics, Inc. $STOKSeptember 4, 2025 | marketbeat.comJonathan Allan Sells 850 Shares of Stoke Therapeutics (NASDAQ:STOK) StockSeptember 4, 2025 | insidertrades.comNuveen LLC Invests $719,000 in Stoke Therapeutics, Inc. $STOKSeptember 4, 2025 | marketbeat.comStoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine ...September 2, 2025 | uk.finance.yahoo.comStoke Therapeutics, Inc. $STOK Shares Sold by Deutsche Bank AGSeptember 2, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Cuts Stake in Stoke Therapeutics, Inc. $STOKSeptember 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDERM, FBIO, AUTL, and STOK Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.38 +0.01 (+0.73%) Closing price 04:00 PM EasternExtended Trading$1.42 +0.04 (+2.54%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Journey Medical NASDAQ:DERM$7.23 -0.22 (-2.95%) Closing price 04:00 PM EasternExtended Trading$7.20 -0.04 (-0.48%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Fortress Biotech NASDAQ:FBIO$3.86 +0.27 (+7.52%) Closing price 04:00 PM EasternExtended Trading$3.84 -0.02 (-0.65%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Stoke Therapeutics NASDAQ:STOK$22.66 +0.59 (+2.67%) Closing price 04:00 PM EasternExtended Trading$22.99 +0.33 (+1.46%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
